Latest Cutaneous lupus erythematosus Stories
Lupus Science & Medicine is launched to provide the latest lupus research and stimulate collaborative efforts to improving the lives of all people affected by lupus WASHINGTON, April 3, 2014
HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"),
Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com.
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with
Brings Total to $6.6 Million to Educate Healthcare Professionals on Front-Lines of Care NEW YORK, Jan.
Reportbuyer.com just published a new market research report:
Scientists from Northwestern Medicine have brought new hope to patients with Lupus. A new nontoxic therapy that suppresses Lupus in blood samples was designed and successfully tested on patients with the autoimmune disease.
- Inward knowledge; understanding; conscience.